Daily oral orforglipron, a nonpeptide GLP-1 receptor agonist, led to up to 14.7% weight loss over 36 weeks in this phase 2 trial. Conducted in adults with obesity or overweight and no diabetes, the study showed that 46-75% of participants achieved at least 10% weight loss. Orforglipron also improved key cardiometabolic markers, with a tolerability profile consistent with other GLP-1 therapies.
Read this publication to explore:
- Weight reduction results by dose group vs placebo
- Improvements in cardiometabolic risk factors
- Safety and GI tolerability outcomes across cohorts